CLINICAL_TRIALS trial_result · 2023-01-19

Clinical Trial Update: Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis [Phase 2]

Phase 2 trial evaluating safety and tolerability of NCX 4251 for acute exacerbations of blepharitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Nicox Ophthalmics, Inc. | Conditions: Blepharitis | Phase 2 | Status: COMPLETED | Results posted: 2023-01-19